ESC 22: Hot Line & Late-breaking Science Video Collection
Published: 24 August 2022
-
Views:
6349 -
Likes:
7
-
Views:
6349 -
Likes:
7
-
6m 50sPart 6 | Session 1 REVIVED-BCIS2, RTC, FRAME-AMI by Dr Mirvat Alasnag
-
9m 51sPart 6 | Session 2 DANCAVAS, DELIVER, SECURE by Dr Purvi Parwani
-
3m 29sPart 6 | Session 3 eBRAVE-AF, CAPLA, INVICTUS by Dr Afzal Sohaib
-
7m 2sPart 6 | Session 4 TIME, SECURE, DANCAVAS by Dr Martha Gulati
-
33m 19sPart 1 | Session 1 View from the Thoraxcenter – ESC 2022 Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
24m 27sPart 1 | Session 2 View from the Thoraxcenter – ESC 2022 Preview Nicolas M Van Mieghem, Joost Daemen
-
17m 13sPart 2 | Session 1 Late-breaker Discussion: The INVICTUS Trial Harriette Van Spall, Ganesan Karthikeyan
-
11m 27sPart 2 | Session 2 Late-breaker Discussion: The DELIVER Trial Harriette Van Spall, Scott Solomon
-
14m 31sPart 2 | Session 3 Late-breaker Discussion: The REVIVED Trial Harriette Van Spall, Divaka Perera
-
11m 5sPart 2 | Session 4 Late-breaker Discussion: The ADVOR Trial Wilfried Mullens, Harriette Van Spall
-
24m 19sPart 3 ESC 22 Guidelines on Cardio-Oncology: Summary & Question Time Teresa López Fernández, Alexander Lyon, Arjun K Ghosh
-
5m 34sPart 4 | Session 1 ASCEND: Aspirin and Omega-3 Fatty Acids in Preventing Heart Failure Michelle Goonasekera
-
2m 29sPart 4 | Session 2 ALL-HEART: Allopurionol in the Treatment of Ischaemic Heart Disease Isla S Mackenzie
-
7m 9sPart 4 | Session 3 PACIFIC-STROKE: Dosing of Asundexian in Pts With Non-Cardioembolic Ischemic Stroke Ashkan Shoamanesh
-
4m 22sPart 4 | Session 4 PACIFIC-AMI: Asundexian on Top of DAPT After Acute Myocardial Infarction John H Alexander
-
6m 26sPart 4 | Session 6 AXIOMATIC-SSP: Milvexian in Additon to Aspirin and Clopidogrel for Secondary Stroke Prevention Mukul Sharma
-
3m 45sPart 4 | Session 7 Artificial Intelligence Detection of Severe Aortic Stenosis Geoffrey Strange
-
7m 25sPart 4 | Session 8 MOMENTUM 3: 5-year Results From HeartMate 3 LVAD Therapy Mandeep Mehra
-
4m 13sPart 4 | Session 9 MASTER DAPT Results at 15M with Prof Valgimigli Marco Valgimigli
-
3m 57sPart 4 | Session 10 APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID Renato D Lopes
-
3m 22sPart 4 | Session 11 The PRE18FFIR Trial: 18F-NaF PET for Vulnerable Coronary Plaque imaging After MI David Newby
-
5m 44sPart 4 | Session 12 FIDELITY: Finerenone in Pts With Chronic Kidney Disease Gerasimos Filippatos
-
4m 44sPart 4 | Session 13 The EMPEROR-POOLED Trial: Clinical Benefits of SGLT2i in Heart Failure Faiez Zannad
-
2m 55sPart 4 | Session 14 The EMMY Trial: Empagliflozin in Patients with Acute MI Harald Sourij
-
4m 51sPart 4 | Session 15 COVID-PACT: Antithrombotic Therapy in Critically Ill COVID-19 Pts David Berg
-
4m 59sPart 4 | Session 16 ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19 Sanjit Jolly
-
5m 51sPart 4 | Session 17 PERSPECTIVE: Sacubitril/Valsartan & Cognitive Function in HFmrEF & HFpEF John JV McMurray
-
1m 29sPart 5 | Session 1 Behind the Heart: Michelle Goonasekera Michelle Goonasekera
-
1m 15sPart 5 | Session 2 Behind the Heart: Isla S Mackenzie Isla S Mackenzie
-
6m 28sPart 5 | Session 3 Behind the Heart: Douglas Bradley Douglas Bradley
-
2m 20sPart 5 | Session 4 Behind the Heart: Ashkan Shoamanesh Ashkan Shoamanesh
-
1m 22sPart 5 | Session 5 Behind the Heart: Mukul Sharma Mukul Sharma
-
1m 18sPart 5 | Session 6 Behind the Heart: Geoffrey Strange Geoffrey Strange
-
4m 30sPart 5 | Session 7 Behind the Heart: Martha Gulati Martha Gulati
-
1m 50sPart 5 | Session 8 Behind the Heart: John H Alexander John H Alexander
-
1m 54sPart 5 | Session 9 Behind the Heart: Renato D Lopes Renato D Lopes
-
1m 16sPart 5 | Session 10 Behind the Heart: David Newby David Newby
-
1m 43sPart 5 | Session 11 Behind the Heart: Faiez Zannad Faiez Zannad
-
1m 8sPart 5 | Session 12 Behind the Heart: Harald Sourij Harald Sourij
-
2m 2sPart 5 | Session 13 Behind the Heart: David Berg David Berg
-
1m 11sPart 5 | Session 14 Behind the Heart: Sanjit Jolly Sanjit Jolly
-
1m 20sPart 5 | Session 15 Behind the Heart: Mirvat Alasnag Mirvat Alasnag
-
4m 30sPart 5 | Session 16 Behind the Heart: Martha Gulati Martha Gulati
-
2m 33sPart 5 | Session 17 Behind the Heart: Purvi Parwani
-
2m 51sPart 5 | Session 18 Behind the Heart: John McMurray John JV McMurray
Overview
What's hot at European Society of Cardiology (ESC) Congress 22?
Stay tuned and browse our curated coverage of the latest data in cardiology.
- For a concise line up of the most awaited trials join Prof Nicolas Van Mieghem and Dr Joost Daemen and their regular View From the Thoraxcenter series.
- For a deeper dive into key clinical trial data and applicability, host, Dr Harriette Van Spall talks with principal investigators in her Late-Breaker Discussion Series.
- Short, accessible Expert Interviews conducted with select faculty focusing on data, patient care and the future of their field.
- To mark the release of the new ESC Guidelines on Cardio-Oncology, we will feature a 10-minute summary and a 10-minute live audience Q&A.
- We asked some of the most prominent researchers today about their pathways in the Behind the Heart series.
Watch our Radcliffe Premiere TV to be transported to Barcelona.
More from this programme
Part 1
View From the Thoraxcenter: Review Series
Part 2
Late-breaker Discussion Series With Dr Harriette Van Spall
Part 3
ESC Guidelines on Cardio-Oncology: Summary & Question Time
Part 4
Hot Line & Late-breaking Interviews
Part 5
Behind the Heart from Barcelona
Part 6
3 Trials That Will Change Your Practice: Reviews
Faculty Biographies
Marco Valgimigli
Deputy Chief of Cardiology
Prof Marco Valgimigli is an Interventional Cardiologist and Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland.
He obtained his medical degree from the University of Bologna, and completed his training in internal medicine at the same university. He received a degree in cardiological sciences at the University of Ferrara and a PhD in interventional cardiology at Erasmus Medical Center in Rotterdam.
Prof Valgimigli’s areas of research are wide ranging and include high-risk percutaneous interventions (PCI); invasive treatment of myocardial ischaemia (MI); reparative medicine with adult stem cells during MI and heart failure; antithrombotic therapy during and after PCI; and prognostic stratification during acute coronary syndromes and MI.